CTTH   $0.029  49.25% Market Open

Last Events:

2023-03-29 Signal in EMA100 changed from bearish reversal to n/a. 2021-05-03 the price crossed down the moving average line and getting closer to the MA, which means that the downside trend weakens.

2023-03-29 Signal in EMA50 changed from bullish reversal to bearish reversal. 2022-11-16 the price crossed down the moving average line and getting closer to the MA, which means that the downside trend weakens.

2023-03-29 Trend Power changed from strong to medium strength.

2023-03-29 Trend changed from down and flat to flat and down.

2023-03-29 Signal in EMA100 changed from n/a to bearish reversal. 2022-10-14 the price crossed down the moving average line and getting closer to the MA, which means that the downside trend weakens.

2023-03-29 Signal in EMA50 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-03-29 Trend Power changed from medium strength to strong.

2023-03-29 Trend changed from flat and down to down and flat.


Current temperature: 0.43
ST: 0, Cor:

Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Buy -
rsi ActivelyBuy ActivelyBuy -
macd ActivelyBuy ActivelyBuy -
stoch Sell Sell -
ma20 - - -
ma50 - - -
ma100 - - -
Candlestick PatternNov. 4, 2022 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US12651E1064
Website https://www.cttpharmaceuticals.com
CTT Pharmaceutical Holdings, Inc. engages in the development of oral drug delivery systems for pain management and treatment. It focuses on fast dissolving drug delivery systems. The company's technology platform includes the development of advanced oral delivery thin wafers infused with both natural and/or synthetic cannabis extracts to deliver treatment as an alternate to smoking and ingestion. Its principal asset is a patented orally administered wafer, an orally administrable wafer comprising at least one physiologically acceptable film forming agent. The company was formerly known as Mindesta Inc. and changed its name to CTT Pharmaceutical Holdings, Inc. in July 2015. The company is based in Ottawa, Canada.